KSP

Kindred unveils strategic partnership with Stats Perform to power Kindred Sportsbook Platform

Retrieved on: 
Tuesday, January 30, 2024
Heart, Partnership, Stats Perform, Kindred Group, KSP, Statistics, Sport

VALLETTA, Malta, Jan. 30, 2024 /PRNewswire/ -- Kindred Group plc (Kindred) continues the development of its proprietary sportsbook platform, Kindred Sportsbook Platform (KSP), by signing a wide-ranging agreement with Stats Perform to utilise RunningBall official in-play sports data feed, Opta player statistics, and an extensive range of content to entertain and inform customers.  High quality and low latency data will enable Kindred customers to enjoy the fastest and most friction-free experience. RunningBall and Opta products and services are important components when supporting this level of differentiation. The content delivered via Stats Perform's new Content Player Pro such as contextual insights, preview videos, live expected goals and in-game momentum will enhance the customer experience. The agreement supports Kindred's ambition to build a superior product and experience with data and differentiation at its heart.

Key Points: 
  • Kindred has signed an extensive agreement with Stats Perform which will give access to Stats Perform's full RunningBall and Opta product suite.
  • VALLETTA, Malta, Jan. 30, 2024 /PRNewswire/ -- Kindred Group plc (Kindred) continues the development of its proprietary sportsbook platform, Kindred Sportsbook Platform (KSP), by signing a wide-ranging agreement with Stats Perform to utilise RunningBall official in-play sports data feed, Opta player statistics, and an extensive range of content to entertain and inform customers.
  • "We are thrilled to announce our expanded strategic partnership with Stats Perform, a move that will unequivocally benefit our valued sports fans and customers.
  • We are delighted that Kindred recognise the value we will unlock together in this exciting new partnership," comments Andrew Ashenden, Chief Betting Officer, Stats Perform.

Kindred unveils strategic partnership with Stats Perform to power Kindred Sportsbook Platform

Retrieved on: 
Tuesday, January 30, 2024
Heart, Partnership, Stats Perform, Kindred Group, KSP, Statistics, Sport

VALLETTA, Malta, Jan. 30, 2024 /PRNewswire/ -- Kindred Group plc (Kindred) continues the development of its proprietary sportsbook platform, Kindred Sportsbook Platform (KSP), by signing a wide-ranging agreement with Stats Perform to utilise RunningBall official in-play sports data feed, Opta player statistics, and an extensive range of content to entertain and inform customers.  High quality and low latency data will enable Kindred customers to enjoy the fastest and most friction-free experience. RunningBall and Opta products and services are important components when supporting this level of differentiation. The content delivered via Stats Perform's new Content Player Pro such as contextual insights, preview videos, live expected goals and in-game momentum will enhance the customer experience. The agreement supports Kindred's ambition to build a superior product and experience with data and differentiation at its heart.

Key Points: 
  • Kindred has signed an extensive agreement with Stats Perform which will give access to Stats Perform's full RunningBall and Opta product suite.
  • VALLETTA, Malta, Jan. 30, 2024 /PRNewswire/ -- Kindred Group plc (Kindred) continues the development of its proprietary sportsbook platform, Kindred Sportsbook Platform (KSP), by signing a wide-ranging agreement with Stats Perform to utilise RunningBall official in-play sports data feed, Opta player statistics, and an extensive range of content to entertain and inform customers.
  • "We are thrilled to announce our expanded strategic partnership with Stats Perform, a move that will unequivocally benefit our valued sports fans and customers.
  • We are delighted that Kindred recognise the value we will unlock together in this exciting new partnership," comments Andrew Ashenden, Chief Betting Officer, Stats Perform.

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

Retrieved on: 
Sunday, December 10, 2023
Toxicokinetics, Spleen, Drug, Human, Neoplasm, Survival, Lymphoid leukemia, Pharmacology, Aplastic anemia, Completeness, Spacecraft, TP53, Mitosis, CD79B, Apoptosis, Mantle cell lymphoma, Myelodysplastic syndrome, Tissue, Literature, DNA, Blood, Society, Cancer, ASH, Biochemistry, KSP, CXCR5, BCL2, CD123, Toxicity, BTK, Poster, Safety, Leukemia, Hepatotoxicity, Patient, CD19, CBC, Humanized antibody, ADC, AML, Therapy, Acute myeloid leukemia, Conjugation, MCL, Fine chemical

PALO ALTO, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the presentation of two preclinical posters at the 65th Annual Meeting of the American Society for Hematology (ASH 2023) for VIP943, for leukemias and myelodysplastic syndrome, and VIP924, for B-cell malignancies.

Key Points: 
  • “We are excited to share new preclinical data for VIP943 and VIP94 with our stakeholders,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • Poster #1435: Selectivity and Safety of VIP943: A novel CD123 Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class.
  • Objective: The poster outlines a series of assays used to characterize the preclinical properties of VIP943, including biochemistry, pharmacology, on-target selectivity and activity, safety, and toxicokinetics.
  • Complete blood counts (CBCs) show that VIP924 had minimal impact on the six elements of the CBC reported in these studies.

Space Programme Backed by Egyptian Businessman Set to Launch Most Powerful UK Reusable Rocket - Karman Space Programme

Retrieved on: 
Wednesday, September 20, 2023
Research, Other Transport, Technology, Security, Transport, Aerospace, Manufacturing, Science, Artificial Intelligence, Other Science, META, KSP, Orion, Deep learning, Imperial, Ingram Micro, Mission control center, Consultant, Machine learning, Child, Artificial intelligence, Imperial College London, Social media, Video game, AI

A university space programme from London are preparing to launch the most powerful British reusable rocket.

Key Points: 
  • A university space programme from London are preparing to launch the most powerful British reusable rocket.
  • This Sunday the Karman Space Programme (KSP) will attempt a two-stage rocket launch to test systems for reuse and recovery of the vehicle, a crucial step towards low-cost, sustainable access to space.
  • The programme is sponsored and funded by CYBRAL - an AI-driven cyber security company..
    KSP Co-founder, Shapol, said, “The support we have received from CYBRAL has been unmatched.
  • More information about Karman Space Programme can be found at: https://www.karmanspace.co.uk/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20230920132895/en/

University Students Set to Launch Most Powerful UK Reusable Rocket - Karman Space Programme

Retrieved on: 
Tuesday, September 19, 2023
Research, Sustainability, Technology, Artificial Intelligence, Environment, University, Education, Satellite, Science, Engineering, Aerospace, Manufacturing, Eclipse, KSP, Orion, 3D, ICL, UK Space Agency, Innovation, Multimedia, Mission control center, VR, Dassault Systèmes, AI, Seko, Social media, Video game, OneWeb

A team of university students in London is preparing to launch the most powerful reusable rocket built by a UK team.

Key Points: 
  • A team of university students in London is preparing to launch the most powerful reusable rocket built by a UK team.
  • On Sunday, September 24th, the student-led Karman Space Programme (KSP) will attempt a two-stage rocket launch to test systems for reuse and recovery of the vehicle, a crucial step towards low-cost, sustainable access to space.
  • The UK Minister for Space at the Department for Science, Innovation and Technology, George Freeman, said: “To see the next generation of space innovators already pushing the boundaries of UK space technology is remarkable and I wish the Karman Space Programme success after their hard work.
  • More information about Karman Space Programme can be found at: https://www.karmanspace.co.uk/ .

KSP, McLaren's Specialty Pharmacy, earns full URAC re-accreditation

Retrieved on: 
Tuesday, August 1, 2023
Accreditation, HIV, Pharmacy, Physician, Cancer, DSM-IV codes, Risk management, Hard, Prescription, Karmanos Cancer Institute, Pharmacist, Pioneer, McLaren Health Care Corporation, Specialty pharmacy, Patient, Patient safety, URAC, National Comprehensive Cancer Network, Hospital, KSP

DETROIT, Aug. 1, 2023 /PRNewswire/ -- KSP, McLaren Health Care's Specialty Pharmacy, has earned full re-accreditation for specialty pharmacy from URAC through August 1, 2026. By achieving this status, KSP has demonstrated its commitment to quality care, enhanced process, patient safety and improved outcomes.

Key Points: 
  • DETROIT, Aug. 1, 2023 /PRNewswire/ -- KSP , McLaren Health Care's Specialty Pharmacy, has earned full re-accreditation for specialty pharmacy from URAC through August 1, 2026.
  • By achieving this status, KSP has demonstrated its commitment to quality care, enhanced process, patient safety and improved outcomes.
  • With this designation, KSP will continue providing specialty agents for various diseases.
  • URAC congratulates KSP on their achievement of Specialty Pharmacy Accreditation.

Standard Lithium Enhances Leadership with Appointment of David Park as Senior Strategic Advisor

Retrieved on: 
Wednesday, July 5, 2023
Lithium, Area studies, Business development, Senior, Atomic energy, SLI, Koch, Texas A&M University, George Mason University, Koch Industries, FRA, LANXESS, PFS, SWA, Retirement, International business, CFO, Knowledge, United, News, NYSE, DFS, Management, Science, KSP, Economics

VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, is pleased to announce the appointment of David Park as Senior Strategic Advisor.

Key Points: 
  • VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, is pleased to announce the appointment of David Park as Senior Strategic Advisor.
  • Mr. Park, a highly experienced executive with a strong energy and industrial sector background, joins Standard Lithium following his retirement from Koch Industries after 28 years.
  • “We are pleased to welcome David to Standard Lithium,” said Robert Mintak, CEO and Director of Standard Lithium.
  • Throughout his career, he consistently delivered outstanding results, underscoring his ability to drive success and generate significant value for Standard Lithium.

Standard Lithium Enhances Leadership with Appointment of David Park as Senior Strategic Advisor

Retrieved on: 
Wednesday, July 5, 2023
Lithium, Area studies, Business development, Senior, Atomic energy, SLI, Koch, Texas A&M University, George Mason University, Koch Industries, FRA, LANXESS, PFS, SWA, Retirement, International business, CFO, Knowledge, United, News, NYSE, DFS, Management, Science, KSP, Economics

VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, is pleased to announce the appointment of David Park as Senior Strategic Advisor.

Key Points: 
  • VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, is pleased to announce the appointment of David Park as Senior Strategic Advisor.
  • Mr. Park, a highly experienced executive with a strong energy and industrial sector background, joins Standard Lithium following his retirement from Koch Industries after 28 years.
  • “We are pleased to welcome David to Standard Lithium,” said Robert Mintak, CEO and Director of Standard Lithium.
  • Throughout his career, he consistently delivered outstanding results, underscoring his ability to drive success and generate significant value for Standard Lithium.

KSP, McLaren's Specialty Pharmacy, recognized as a Leader in Performance Measurement

Retrieved on: 
Tuesday, May 9, 2023
Communication, Report, Accreditation, Therapy, Gastroenterology, HIV, Pharmacy, Risk management, LPM, URAC, Quality, Pharmacist, Karmanos Cancer Institute, Pioneer, McLaren Health Care Corporation, Specialty pharmacy, Patient, MMM, McLaren, Research, National Comprehensive Cancer Network, Health, Neurology, Empowerment, Oncology, Hospital, Nursing, KSP

DETROIT, May 9, 2023 /PRNewswire/ -- The Utilization Review Accreditation Commission (URAC) has awarded KSP, McLaren's Specialty Pharmacy, as a 2022 Pioneer in URAC's Leaders in Performance Measurement (LPM) in their recognition program. This distinction shows that KSP has demonstrated a commitment to improving healthcare quality through performance measurement.

Key Points: 
  • This distinction shows that KSP has demonstrated a commitment to improving healthcare quality through performance measurement.
  • Being a Pioneer in Performance Management means KSP is going above mandatory reporting requirements, which helps to provide insights into cutting-edge measurement concepts.
  • Within the URAC's LPM programs, this award recognizes KSP as a leader among the Specialty Pharmacy programs.
  • When evaluating specialty pharmacies, the URAC's Quality, Research and Measurement Team considered data collected between January 1 through December 31, 2022.

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
CLL, Lymphoma, AACR, ASH, Therapy, KSP, Doctor of Philosophy, Chronic lymphocytic leukemia, Follicular lymphoma, Lymphoid leukemia, DLBCL, Neoplasm, PALO, Survival, Cancer, Toxicity, Antibody, B-cell lymphoma, PDX, Plasma, Patient, Mantle cell lymphoma, CXCR5, Mouse, Immunohistochemistry, ADC, MCL, Poster, IND, Human, Safety, Pharmaceutical industry, Vaccine, Medical imaging

PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • This modification allows for intracellular accumulation of VIP716 in CXCR5+ tumor cells, providing greater efficacy, and prevents cellular penetration into healthy tissues, reducing toxicity.
  • “We are thrilled to continue advancing our bioconjugation platform with our newest ADC, VIP924,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx.
  • “At AACR, VIP924 showed meaningful preclinical activity in a panel of lymphoma cell lines and in cell line-derived and patient-derived lymphoma mouse models.